Shares of Gritstone Oncology Inc (NASDAQ: GRTS) climbed 3.7% in after-market trading to $9.8 at the last check. During the regular trading on Tuesday, Gritstone stock closed the session at $9.45, decreasing -2.38 percent, or -$0.23.
Over a year, the GRTS stock rose 24.18%, and within the last week, the stock moved up 9.88%. The GRTS stock has surged in the absence of any relevant news, but a recent update is likely to serve as a better guide.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Recent update:
Gritstone is a clinical-stage biotech that develops immunotherapies against multiple types of cancer as well as infectious diseases. A key component of the GRTS product development process is the integration of two key pillars:
Firstly: A proprietary machine learning-based platform, Gritstone EDGETM, which predicts antigens on the surface of cells, such as those derived from tumors, which can be scanned by the immune system.
Secondly: Another advantage of these antigens is that they can be employed by their manufacturers to create potent immunotherapies aimed at specifically attacking and destroying disease-causing cells.
In a Phase 1 study under GRTS’s “CORAL” program, Gritstone last month announced that it has dosed the first patient with its candidate vaccine COVID-19.
- Through the GRTS study, it was hoped to find out if using its self-amplifying mRNA (SAM) and adenoviral vectors with SARS-CoV-2 virus antigens would be immunogenic and safe.
- The three antigens under study by GRTS include both Spike Antigen and other antigens not included in current licensed vaccines.
- Infectious Diseases Clinical Research Consortium (IDCRC) funded the Phase 1 trial of Gritstone (GRTS) by the National Institute of Allergy and Infectious Diseases (NIAID).
